X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Freeline gains rights to develop and commercialise AAV-based gene therapies for certain cardiac conditions using key targets identified by Forcefield.
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Freeline Therapeutics
Deal Size: $0.6 million Upfront Cash: Undisclosed
Deal Type: Agreement April 04, 2023
Details:
Positive preclinical data of Chrdl1 in Science Translational Medicine, published today, outlines the mechanisms of the three proteins, which have been shown to restore heart function following a heart attack in mice.
Lead Product(s): Chrdl1
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
